Featured Research

from universities, journals, and other organizations

Dementia: Cerebrolysin shows promise

Date:
January 31, 2013
Source:
Wiley
Summary:
Dementia patients may benefit from a promising new treatment called Cerebrolysin, according to the results of a systematic review. The authors brought together the most up-to-date evidence on Cerebrolysin as a treatment for vascular dementia.

Dementia patients may benefit from a promising new treatment called Cerebrolysin, according to the results of a systematic review published in The Cochrane Library. The authors brought together the most up-to-date evidence on Cerebrolysin as a treatment for vascular dementia.

Vascular dementia is a common form of dementia caused by damage to the network of blood vessels supplying the brain. Some of the symptoms are similar to those associated with Alzheimer's disease and stroke but in particular those with vascular dementia often experience difficulty thinking quickly, concentrating and communicating, as well as seizures and severe confusion. There is currently no definitive treatment for vascular dementia. Cerebrolysin is a drug treatment made from pig brain proteins that has produced positive results against vascular dementia, although inconsistently.

The researchers reviewed data from six randomized controlled trials involving 597 people in total. All were given Cerebrolysin intravenously in different daily concentrations and for different treatment periods, from a few weeks to three years, depending on the trial. Compared to standard care alone or placebos, Cerebrolysin significantly improved cognitive function, which was assessed with scales testing recall, arithmetic or other cognitive abilities. It had a small positive effect on patients' overall clinical state. There was also some suggestion that long-term treatment was associated with greater benefits, although only two trials looked at long-term effects.

"Our review suggests that Cerebrolysin can help improve cognitive and global function in patients with mild to moderate severity vascular dementia," said researcher Li He of the Department of Neurology at Sichuan University in Sichuan, China. "The results are promising but due to low numbers of trials, inconsistencies between trials, risk of bias in the way some of the trials were conducted and lack of long-term follow-up, we cannot yet recommend Cerebrolysin as a routine treatment for vascular dementia."

None of those involved in studies reported serious side effects due to taking the drug and non-serious side effects were no more common in those who took the drug compared to control groups. "This indicates to us that Cerebrolysin is safe and well tolerated by patients with vascular dementia," said He. "But the fact that it has to be given in regular intravenous infusions means it could be impractical for use on a large scale."


Story Source:

The above story is based on materials provided by Wiley. Note: Materials may be edited for content and length.


Journal Reference:

  1. Ning Chen, Mi Yang, Jian Guo, Muke Zhou, Cairong Zhu, Li He. Cerebrolysin for vascular dementia. The Cochrane Library, 2013; DOI: 10.1002/14651858.CD008900.pub2

Cite This Page:

Wiley. "Dementia: Cerebrolysin shows promise." ScienceDaily. ScienceDaily, 31 January 2013. <www.sciencedaily.com/releases/2013/01/130131084614.htm>.
Wiley. (2013, January 31). Dementia: Cerebrolysin shows promise. ScienceDaily. Retrieved August 27, 2014 from www.sciencedaily.com/releases/2013/01/130131084614.htm
Wiley. "Dementia: Cerebrolysin shows promise." ScienceDaily. www.sciencedaily.com/releases/2013/01/130131084614.htm (accessed August 27, 2014).

Share This




More Mind & Brain News

Wednesday, August 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Have You Ever Been 'Sleep Drunk?' 1 in 7 Has

Have You Ever Been 'Sleep Drunk?' 1 in 7 Has

Newsy (Aug. 26, 2014) A study published in the journal "Neurology" interviewed more than 19,000 people and found 15 percent suffer from being "sleep drunk." Video provided by Newsy
Powered by NewsLook.com
Does Medical Marijuana Reduce Painkiller Overdose Deaths?

Does Medical Marijuana Reduce Painkiller Overdose Deaths?

Newsy (Aug. 26, 2014) A new study found fewer deaths from prescription drug overdoses in states that have legalized medical marijuana. But experts disagree on the results. Video provided by Newsy
Powered by NewsLook.com
Heart Group: E-Cigarettes May Help Smokers Quit

Heart Group: E-Cigarettes May Help Smokers Quit

AP (Aug. 25, 2014) The American Heart Association's first policy statement on electronic cigarettes backs them as a last resort to help smokers quit and calls for more regulation to keep them away from youth. (Aug. 25) Video provided by AP
Powered by NewsLook.com
Doctors Push For Later Start Times As School Year Kicks Off

Doctors Push For Later Start Times As School Year Kicks Off

Newsy (Aug. 25, 2014) The American Academy of Pediatrics is the latest group pushing for middle schools and high schools to start later, for the sake of their kids. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins